With 0.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.39 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $0.8407 whereas the lowest price it dropped to was $0.7702. The 52-week range on LUCD shows that it touched its highest point at $1.58 and its lowest point at $0.63 during that stretch. It currently has a 1-year price target of $3.50. Beta for the stock currently stands at 1.43.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LUCD was down-trending over the past week, with a drop of -17.99%, but this was down by -24.16% over a month. Three-month performance dropped to -5.11% while six-month performance rose 8.82%. The stock lost -42.43% in the past year, while it has lost -44.06% so far this year. A look at the trailing 12-month EPS for LUCD yields -1.13 with Next year EPS estimates of -0.61. For the next quarter, that number is -0.17. This implies an EPS growth rate of 84.60% for this year and 30.90% for next year.
Float and Shares Shorts:
At present, 51.60 million LUCD shares are outstanding with a float of 20.91 million shares on hand for trading. On 2024-11-29, short shares totaled 0.42 million, which was 70.999996 higher than short shares on 1730332800. In addition to Dr. Lishan Aklog M.D. as the firm’s Chairman & CEO, Mr. Shaun M. O’Neill M.B.A. serves as its President & COO.
Institutional Ownership:
Through their ownership of 0.04182 of LUCD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, LUCD reported revenue of $1172000.0 and operating income of -$11694000.0. The EBITDA in the recently reported quarter was -$11398000.0 and diluted EPS was -$0.25.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LUCD since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LUCD analysts setting a high price target of 7.0 and a low target of 2.0, the average target price over the next 12 months is 3.5. Based on these targets, LUCD could surge 786.08% to reach the target high and rise by 153.16% to reach the target low. Reaching the average price target will result in a growth of 343.04% from current levels.
Analysts have provided yearly estimates in a range of -$0.70276 being high and -$1.0914 being low. For LUCD, this leads to a yearly average estimate of -$0.89.
